Show simple item record

dc.creatorMeleveedu, Kapil S
dc.creatorMiskovsky, John
dc.creatorMeharg, Joseph
dc.creatorAbdelrahman, Abd
dc.creatorTandon, Richa
dc.creatorMoody, Ashley E.
dc.creatorDasilva, Priscilla
dc.creatorMasse, Gabrielle
dc.creatorLaPorte, Jason
dc.creatorSaied Calvino, Abdul
dc.creatorAllen, Greg
dc.creatorEl-Bizri, Rabih
dc.creatorRoberts, Todd
dc.creatorArmenio, Vincent
dc.creatorKatz, Steven C.
dc.date.accessioned2020-09-30T15:35:09Z
dc.date.available2020-09-30T15:35:09Z
dc.date.created2020
dc.identifier.issn2590-1532spa
dc.identifier.otherhttps://doi.org/10.1016/j.cytox.2020.100035spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/14019
dc.description.abstractThe SARS-CoV-2 virus responsible for the COVID-19 pandemic can result in severe or fatal disease in a subset of infected patients. While the pathogenesis of severe COVID-19 disease has yet to be fully elucidated, an overexuberant and harmful immune response to the SARS-CoV-2 virus may be a pivotal aspect of critical illness in this patient population. The inflammatory cytokine, IL-6, has been found to be consistently elevated in severely ill COVID-19 patients, prompting speculation that IL-6 is an important driver of the pathologic process. The inappropriately elevated levels of inflammatory cytokines in COVID-19 patients is similar to cytokine release syndrome (CRS) observed in cell therapy patients. We sought to describe outcomes in a series of severely ill patients with COVID-19 CRS following treatment with anti-IL-6/IL-6-Receptor (anti-IL-6/IL-6-R) therapy, including tocilizumab or siltuximab. At our academic community medical center, we formed a multi-disciplinary committee for selecting severely ill COVID-19 patients for therapy with anti-IL-6 or IL-6-R agents. Key selection criteria included evidence of hyperinflammation, most notably elevated levels of C-reactive protein (CRP) and ferritin, and an increasing oxygen requirement. By the data cutoff point, we treated 31 patients with anti-IL-6/IL6-R agents including 12 who had already been intubated. Overall, 27 (87%) patients are alive and 24 (77%) have been discharged from the hospital. Clinical responses to anti-IL-6/IL-6-R therapy were accompanied by significant decreases in temperature, oxygen requirement, CRP, IL-6, and IL-10 levels. Based on these data, we believe anti-IL-6/IL-6-R therapy can be effective in managing early CRS related to COVID-19 disease. Further study of anti-IL-6/IL-6-R therapy alone and in combination with other classes of therapeutics is warranted and trials are underway.spa
dc.format.extent8 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherCytokine: Xspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectInfectious diseasespa
dc.subjectSARS-CoV-2spa
dc.subjectIL-6spa
dc.subjectC-reactive proteinspa
dc.titleTocilizumab for severe COVID-19 related illness – A community academic medical center experiencespa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.identifier.doihttps://doi.org/10.1016/j.cytox.2020.100035spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record